Study to Test the Combination of Voriconazole and Anidulafungin in Patients Who Have, or Are Thought to Have, Invasive Aspergillosis and Who Are Unable to Take a Common Antifungal Therapy (Polyene)

Stopped early · Phase 4

Conditions studied: Aspergillosis

In brief

This study will test the effectiveness and the safety of giving two antifungal agents (voriconazole and anidulafungin) together to treat invasive aspergillosis in patients who are unable to tolerate polyene therapy.

Key facts

Study ID

NCT00620074

Run by

Pfizer

People needed

6

Starts

2008-08-01

Expected to finish

2009-02-01

Last updated by the study team

2010-02-15

Who can join

Age: 18 and older. Sex: any. Healthy volunteers: not accepted.

You may qualify if…

• Proven or probable invasive aspergillosis. Patient is intolerant to polyene therapy.

You may not qualify if…

• Patients with invasive aspergillosis for more than 30 days at the time of study entry. Patients with uncontrolled bacterial or viral infection at the time of study entry. Patients with significant liver dysfunction or who are taking certain medications which interact with voriconazole.

Where it is running

• Pfizer Investigational Site — Atlanta, Georgia, United States
• Pfizer Investigational Site — Detroit, Michigan, United States
• Pfizer Investigational Site — Fort Worth, Texas, United States
• Pfizer Investigational Site — Fort Worth, Texas, United States

Full record on ClinicalTrials.gov

Trial information comes from ClinicalTrials.gov and is refreshed daily. TrialsForMe does not provide medical care and does not run the studies it lists.